Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.252
Peer-review started: September 12, 2020
First decision: September 24, 2020
Revised: October 6, 2020
Accepted: October 27, 2020
Article in press: October 27, 2020
Published online: January 6, 2021
Processing time: 111 Days and 2.9 Hours
Debate exists regarding the use of thermal ablation (TA) to treat papillary thyroid carcinoma (PTC). Some studies have recommended TA as a new, efficient and safe technology for PTC. In this article, we report one case of a residual tumor and central lymph node metastasis (CLNM) after TA for PTC.
A 63-year-old female underwent bilateral ultrasound (US)-guided radiofrequency ablation for PTC. Three months later, she was diagnosed as thyroid cancer with suspected CLNM by US and contrast-enhanced computed tomography. The subsequent fine-needle aspiration (FNA) biopsies were negative. Due to her strong personal preference, she underwent total thyroidectomy and central lymph node dissection. Local tissue adhesion and a difficult dissection were noted during the operation. The pathology of the frozen sections during the operation was still negative. The final pathology results of paraffin-embedded sections revealed residual tumor cells at the edge of the PTC and CLNM.
TA may lead to a residual tumor in patients with PTC. Follow-up using US and FNA biopsy may not be adequate to evaluate the residual tumor. TA should be carefully considered in PTC treatment.
Core Tip: Thermal ablation may lead to a residual tumor in patients with papillary thyroid carcinoma. Follow-up using ultrasound and fine-needle-aspiration biopsy may not be adequate to evaluate the residual tumor. Therefore, thermal ablation of papillary thyroid carcinoma should be carefully considered.